Page R, Boolell M, Kalfas A, Sawyer S, Pestell R, Ward G, Alford F
Endocrine Unit, St Vincent's Hospital, Melbourne, Victoria.
Clin Endocrinol (Oxf). 1991 Dec;35(6):509-17. doi: 10.1111/j.1365-2265.1991.tb00936.x.
We wished to assess the contributions of insulin secretion, insulin sensitivity and glucose-mediated glucose disposal to glucose tolerance in subjects exposed to chronic glucocorticoid excess.
Patients with Cushing's disease were subjected to a frequently sampled intravenous glucose tolerance test before and at least 3 months after curative surgery and compared to a control group.
Seven patients with clinical and biochemically proven pituitary dependent Cushing's disease and 10 healthy control subjects were studied.
Paired glucose and insulin plasma profiles were analysed by the Minimal Model method of Bergman, which provided simultaneous estimates of the glucose decay rate, insulin secretion, insulin sensitivity and glucose-mediated and non-insulin-mediated glucose disposal. Data were evaluated by non-parametric statistical analysis and reported as median and interquartile ranges.
Basal glucose, insulin, C-peptide and glucagon levels were significantly raised preoperatively and fell towards normal post-operatively. Glucose tolerance assessed as glucose decay rate was reduced significantly preoperatively (pre: 1.3 (0.8-2.0) vs post: 1.6 (1.5-2.6) per min x 10(2), P less than 0.05). First phase insulin release was similar in the Cushing's disease and control subjects. In contrast, second phase insulin release was significantly greater preoperatively and remained high post-operatively compared to control subjects (pre: 18.8 (16.7-23.6) vs post: 16.7 (8.5-18.8) vs control 11.1 (4.5-15.4) mU/g/min2 x 10(-2), P less than 0.002). Median insulin sensitivity was reduced by 60% preoperatively in the Cushing's disease subjects compared to the post-operative Cushing's disease and control subjects (pre: 2.1 (1.3-4.2) vs post: 5.0 (3.2-7.3) vs control 5.1 (2.2-7.2) per min/mU/l x 10(4)). Median glucose-mediated glucose disposal was reduced by 40% in the pre and post-operative Cushing's disease subjects compared to the control group (pre: 1.1 (0.6-2.1) vs post: 1.1 (0.6-2.1) vs control 1.9 (1.4-2.6) per min x 10(2)), but this was not statistically significant. However, non-insulin-mediated glucose disposal was significantly reduced in the preoperative Cushing's disease subjects (pre: 0.55 (0.08-1.59) vs control 1.43 (0.94-2.27) per min x 10(2), P less than 0.05). In the Cushing's disease subjects, glucose tolerance correlated with both insulin sensitivity (rs = 0.84, P less than 0.01) and non-insulin-mediated glucose disposal (rs = 0.56, P less than 0.05). The fractional clearance rate of insulin was unaltered by Cushing's disease.
Cushing's disease subjects are characterized by impaired glucose tolerance due to both reduced insulin sensitivity and non-insulin-mediated glucose disposal, in the presence of enhanced insulin secretion.
我们希望评估胰岛素分泌、胰岛素敏感性和葡萄糖介导的葡萄糖处置对长期暴露于糖皮质激素过量的受试者糖耐量的贡献。
对库欣病患者在根治性手术前和术后至少3个月进行频繁采样的静脉葡萄糖耐量试验,并与对照组进行比较。
研究了7例临床和生化检查证实为垂体依赖性库欣病的患者和10名健康对照者。
采用伯格曼最小模型法分析配对的血糖和胰岛素血浆曲线,该方法可同时估算葡萄糖衰减率、胰岛素分泌、胰岛素敏感性以及葡萄糖介导和非胰岛素介导的葡萄糖处置。数据通过非参数统计分析进行评估,并报告为中位数和四分位数间距。
术前基础血糖、胰岛素、C肽和胰高血糖素水平显著升高,术后降至正常。以葡萄糖衰减率评估的糖耐量术前显著降低(术前:1.3(0.8 - 2.0)对术后:1.6(1.5 - 2.6)每分钟×10²,P < 0.05)。库欣病患者和对照者的第一相胰岛素释放相似。相比之下,与对照者相比,库欣病患者术前第二相胰岛素释放显著增加,术后仍保持较高水平(术前:18.8(16.7 - 23.6)对术后:16.7(8.5 - 18.8)对对照者11.1(4.5 - 15.4)mU/g/min²×10⁻²,P < 0.002)。与术后库欣病患者和对照者相比,库欣病患者术前胰岛素敏感性中位数降低了60%(术前:2.1(1.3 - 4.2)对术后:5.0(3.2 - 7.3)对对照者5.1(2.2 - 7.2)每分钟/mU/l×10⁴)。与对照组相比,术前和术后库欣病患者葡萄糖介导的葡萄糖处置中位数降低了40%(术前:1.1(0.6 - 2.1)对术后:1.1(0.6 - 2.1)对对照者1.9(1.4 - 2.6)每分钟×10²),但这无统计学意义。然而,术前库欣病患者非胰岛素介导的葡萄糖处置显著降低(术前:0.55(0.08 - 1.59)对对照者1.43(0.94 - 2.27)每分钟×10²,P < 0.05)。在库欣病患者中,糖耐量与胰岛素敏感性(rs = 0.84,P < 0.01)和非胰岛素介导的葡萄糖处置(rs = 0.56,P < 0.05)均相关。库欣病对胰岛素的分数清除率无影响。
库欣病患者的特征是在胰岛素分泌增加的情况下,由于胰岛素敏感性降低和非胰岛素介导的葡萄糖处置受损而导致糖耐量受损。